文献速递药疹与重症皮肤不良反应

外用 vs 系统性糖皮质激素治疗DRESS综合征的真实世界多中心回顾性队列研究

Topical versus systemic corticosteroids for drug reaction with eosinophilia and systemic symptoms syndrome: Real-world outcomes from a multicenter retrospective cohort.
PubMed 文献 · J Am Acad Dermatol · 2026-04-27

该多中心回顾性队列研究纳入359例住院DRESS成人患者,比较初始外用糖皮质激素与系统性糖皮质激素的结局。经重叠倾向评分加权后,两组30天死亡率与出院率无显著差异,45%外用组后续需升级为系统性治疗,全队列19%仅用外用激素即成功管理。

要点

  • 初始外用激素组45%后续需升级为系统性治疗
  • 加权后两组30天死亡率与出院率无显著差异
  • 全队列19%仅用外用激素即成功管理

核心结论

  • 初始外用与系统性糖皮质激素治疗的结局无显著差异。
  • 全队列19%仅用外用糖皮质激素即成功管理,支持其作为潜在一线选择并需密切监测。

研究设计与样本

  • 多中心回顾性队列研究,纳入2家三级中心2012-2021年住院的359例DRESS成人患者。
  • 按初始治疗分为仅外用糖皮质激素组(124例,35%)与系统性±外用糖皮质激素组(235例,65%)。
  • 采用重叠倾向评分加权调整人口学、合并症及基线严重度标志物。

主要发现

  • 外用组56例(45%)后续需升级为系统性治疗。
  • 加权30天死亡率:外用组2.0/1000人日,系统性组2.9/1000人日(HR 1.56;95%CI 0.19-12.94)。
  • 30天出院率:外用组76.2,系统性组92.8(HR 1.22;95%CI 0.87-1.71)。

临床怎么用

  • 对部分住院DRESS患者,可考虑初始外用糖皮质激素并密切监测。
  • 需警惕外用组约45%患者后续需升级为系统性治疗。

局限性

  • 回顾性设计。
  • 缺乏长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe cutaneous adverse reaction for which systemic corticosteroids are widely used; however, emerging evidence suggests that topical corticosteroids may be sufficient in selected cases. OBJECTIVE: To compare outcomes of initial topical corticosteroid versus systemic corticosteroid therapy in hospitalized DRESS patients. METHODS: We conducted a multicenter retrospective cohort study of adults hospitalized with DRESS at 2 tertiary centers (2012-2021). Patients were categorized by initial therapy as topical corticosteroids only or systemic corticosteroids. Primary outcomes were 30-day mortality and discharge. Overlap propensity score weighting adjusted for demographics, comorbidities, and baseline severity markers. RESULTS: Among 359 patients, 124 (35%) were initially treated with topical and 235 (65%) with systemic ± topical corticosteroids; 56 (45%) in the topical group subsequently required escalation to systemic therapy. Weighted 30-day mortality rates were 2.0 and 2.9 per 1000 person-days for topical and systemic groups, respectively (hazard ratio: 1.56; 95% confidence interval: 0.19-12.94). Thirty-day discharge rates were 76.2 and 92.8, respectively (hazard ratio: 1.22; 95% confidence interval: 0.87-1.71). LIMITATIONS: Retrospective design, lack long-term follow-up. CONCLUSIONS: Outcomes did not differ significantly by initial therapy. Of the whole cohort, 19% were successfully managed with topical corticosteroids alone, supporting their role as a potential first-line approach with careful monitoring.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Salciccioli I, Wang J, Jiang B, et al. Topical versus systemic corticosteroids for drug reaction with eosinophilia and systemic symptoms syndrome: Real-world outcomes from a multicenter retrospective cohort. J Am Acad Dermatol. 2026. PMID: 42055292. doi:10.1016/j.jaad.2026.04.1928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。